Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Published online

Journal Article

PURPOSE: Single center studies found that UroVysion FISH (UroVysion) positive results were associated with recurrence in non-muscle invasive bladder cancer (NMIBC) treated with intravesical BCG. Our goal was to validate these findings. MATERIALS AND METHODS: We conducted a prospective, multicenter, diagnostic trial to determine whether UroVysion can predict recurrence or progression in patients with primary high grade NMIBC slated to receive BCG. UroVysion testing was performed prior to first instillation of BCG, prior to 6th instillation, and at 3 months cystoscopy. The performance of UroVysion was evaluated. RESULTS: 150 patients were enrolled, including 68 with Ta tumors, 41 with T1 disease, 26 with CIS alone, and 15 with papillary plus CIS. At 9 months of follow-up, there were 46 events, (37 recurrences and 9 progressions). The hazard ratio for events with positive UroVysion was 2.59 [95%CI: 1.42-4.73] for baseline test, 1.94 [95%CI: 1.04-3.59] for 6-week test, and 3.22 [95%CI: 1.65-6.27] at 3-months. Patients with positive results at baseline, 6 weeks and 3 months had events 55% of the time and patients with negative results at each time point had no event 76% of the time. CONCLUSIONS: The study validated that a positive UroVysion test was associated with a 3.3-fold increased risk of recurrence. The test may be useful in risk-stratifying patients entering clinical trials who fail to respond to induction therapy. However, using the test to change management decisions is limited due to discordance between results and outcomes as well as variance of tests results over time.

Full Text

Duke Authors

Cited Authors

  • Lotan, Y; Inman, BA; Davis, LG; Kassouf, W; Messing, E; Daneshmand, S; Canter, D; Marble, HT; Joseph, AM; Jewell, S; Boorjian, SA

Published Date

  • May 23, 2019

Published In

Start / End Page

  • 101097JU0000000000000355 -

PubMed ID

  • 31120373

Pubmed Central ID

  • 31120373

Electronic International Standard Serial Number (EISSN)

  • 1527-3792

Digital Object Identifier (DOI)

  • 10.1097/JU.0000000000000355


  • eng

Conference Location

  • United States